2020-21 Principles of Pediatric Clinical Pharmacology – Learning Objectives
10/7/2020: Ontogeny of Drug Biotransformation
Lecture Speaker: Jean Dinh
Learning Objectives:
Review basic concepts relevant to a discussion of drug biotransformation in a pediatric context
Developmental trajectories
Regulation of endogenous molecules during growth and development
Discuss specific Phase 1 and Phase 2 pathways
CYP2D6
CYP3A4
CYP2C19
CYP2B6
UGT2B7
Present a basic strategy for investigating a specific drug or drug-related event in children
10/14/2020: Influence of Physiologic Changes in The Developing Gastrointestinal Tract on Drug Absorption & Disposition in Children
Lecture Speaker: Valentina Shakhnovich
Learning Objectives:
Review developmental changes in the maturing pediatric digestive tract
Extrahepatic focus
Influence on peroral drug absorption/disposition
Implications for rectally-administered drugs
Discuss influences of diet, disease and the microbiome on drug absorption/disposition
Provide clinical examples and identify gaps in knowledge
10/21/2020: Ontogeny of Transporters
Lecture Speaker: Saskia deWildt
Learning Objectives:
Explain the clinical relevance of membrane transporters in pediatric drug therapy and discus several examples
Describe transporter specific developmental patterns
List research approaches for studying pediatric drug transporters
Identify major challenges in elucidating the human ontogeny of drug transporters
10/28/2020: Pharmacogenomics and Bioinformatics in Drug Discovery
Lecture Speaker: Anil Jegga
Learning Objectives:
Introduce and give an overview of some of the state-of-art databases and servers that can be used for pharmacogenomics research and drug discovery
Explain how existing data can be harnessed to “guide” or “inform” translational medicine
To provide examples of the application of data repurposing for drug discovery
11/4/2020: Pharmacokinetics and Pharmacodynamics of Protein Therapeutics
Lecture Speaker: Bernd Meibohm
Learning Objectives:
Understand the mechanistic basis for drug disposition of therapeutic proteins and how it differs from traditional small molecule drugs
Appreciate the impact and challenges of drug-target interaction on drug disposition
Explain the impact of immunogenicity on the pharmacokinetics (PK) and pharmacodynamics (PD) of therapeutic proteins
Identify factors in the PK and PD of therapeutic proteins that are modulated by childhood development
12/9/2020: Optimal Study Design in Clinical Pharmacology Research
Lecture Speaker: Dionna Green
Learning Objectives:
List enrichment strategies that have been utilized in pediatric drug development studies
Discuss the placebo effect in pediatric patients and why this is a problem in drug development
Explain how decisions regarding age group breakdown should be made and supported in a drug development program
Discuss pediatric extrapolation and its role in study planning
List the major reasons for pediatric study failures and ways to avoid these pitfalls
12/16/2020: Combining “Bedside" and Clinical Research Data to Inform Disease Progression and Outcomes/Biomarker Selection – Learning and Confirming
Lecture Speaker: Diane Mould
Learning Objectives:
Understand the concept of disease progression versus disease activity
Review the pharmacology of biologic agents and some of the issues associated with dosing metrics as applied to pediatric patients
Understand the relationship between PK and PD commonly seen with biologic agents used to treat inflammatory disease
Understand the concept of using Bayesian adaptive dosing and monitoring of individual PK parameters as a metric of disease activity for biologics
1/6/2021: Metabolomics: Enabling Tools for Precision Medicine
Lecture Speaker: Rima Kaddurah-Daouk
Learning Objectives:
Recognize metabolomics tools used for classification and subclassification of human diseases.
Identify how metabolomics data can be used to inform about treatment outcomes and how it compliments genomics data.
Discuss how exposome diet gut microbiome genome and metabolome connect and collectively influence treatment outcomes.
1/13/2021: Pharmaco-omics: Implications for Clinical Pharmacology
Lecture Speaker: Richard Weinshilboum
Learning Objectives:
Briefly introduce the “omics” techniques being applied to clinical pharmacology
Provide examples of the application of multiple omics to study drug response phenotypes
Outline the use of multiple omics data to “guide” or “inform” genomic studies
1/21/2021: Pharmacotherapy of Epilepsy in Chilren
Lecture Speaker: Tracy Glauser
Describe the classification of seizure types and epilepsy syndromes and its impact on medication selection for children with epilepsy
Understand the pharmacokinetic and pharmacodynamic variability associated with antiepileptic medications.
Understand the importance of clinical pharmacology in medication management and ultimate outcome
1/27/2021: Pharmacologic Management of Neonatal Seizures
Lecture Speaker: Janet Soul
Learning Objectives:
Describe the pathophysiology of acute symptomatic seizures and neonatal-onset epilepsy
Interpret the evidence regarding the efficacy and safety of anti-seizure medications used currently to treat neonatal seizures
Describe the treatment of neonatal seizures and epilepsy related to rare neurogenetic and neurometabolic disorders
2/3/2021: Contemporary Pediatric Sepsis from Start to Finish
Lecture Speaker: Jerry Zimmerman
Learning Objectives:
Review the epidemiology and impact of pediatric sepsis
Discuss novel (pediatric) sepsis diagnostic modalities
Summarize the treatment approach for sepsis, beginning with the sepsis bundle
Emphasize the declining mortality, but increasing long-term morbidity around pediatric sepsis
2/10/2021: Pharmacotherapy of Pediatric Critical Care
Lecture Speaker: Athena Zuppa
Learning Objectives:
Understand the impact of critical illness on drug disposition
Understand how PK modeling techniques can help inform dosing guidance in the population if critically ill children
2/17/2021: Pharmacotherapy to Treat Pediatric Obesity
Lecture Speaker: Jack Yanovski
Learning Objectives:
Describe the limited data supporting the use of anorexiant agents to treat childhood obesity
Describe the limited evidence supporting the use of malabsorptive agents to treat childhood obesity
Describe the limited data evidence supporting the use of therapies that diminish insulin secretion to treat childhood obesity
Understand the mechanisms of action of new agents approved for use in adults over the past year but not yet studied in pediatric samples
2/24/2021: Developmental Toxicology
Lecture Speaker: Pertti Hakkinen
Learning Objectives:
Be able to discuss what development toxicology is and how it compares to reproductive toxicology and developmental pharmacology.
Become knowledgeable about new tools and approaches being used by toxicologists.
Become knowledgeable about online sources of information to stay up-to-date.
3/3/2021: Pharmacotherapy of Type 1 Diabetes in Children
Lecture Speaker: Eda Cengiz
Learning Objectives:
Summarize the status of diabetes management in children with type 1 diabetes and basic principles of diabetes pharmacotherapy in the pediatric population.
Discuss challenges and unmet needs of diabetes pharmacotherapy in children with type 1 diabetes and opportunities to address the unmet needs.
Review recent advances in pediatric diabetes pharmacotherapy and the impact of diabetes technology in improving treatment of diabetes.
3/17/2021: Pharmacotherapy of Type 2 Diabetes in Youth
Lecture Speaker: Philip Zeitler
Learning Objectives:
Describe the evidence base for management of glycemic and non-glycemic aspects of type 2 diabetes in adolescents
Review the various classes of medications available for treatment of type 2 diabetes in youth
Understand the pros and cons of different treatment approaches for type 2 diabetes in youth
3/24/2021: Pharmacotherapy of Pediatric Heart Failure
Lecture Speaker: Joseph Rossano
Learning Objectives:
Understand the current knowledge of the pharmacotherapy of pediatric heart failure
Understand the gaps in knowledge on the pharmacotherapy of pediatric heart failure
Understand the need for ongoing research in the pharmacotherapy of pediatric heart failure
3/31/2021: Pharmacotherapy of Pediatric Arrhythmias
Lecture Speaker: Santiago Valdes
Learning Objectives:
Identify the classification and mechanism of action of anti-arrhythmic medications.
Discuss the choice of anti-arrhythmic medication for different pediatric arrhythmias.
List adverse effects of the most common anti-arrhythmic medications.
4/7/2021: Extemporaneous Formulations – Growth, Issues, and Solutions
Lecture Speaker: Lisa Ashworth
Learning Objectives:
Describe the role, importance, growth, and scope of pharmaceutical compounding
List some of the issues related to pharmaceutical compounding
Discuss the activities related to addressing these issues
Explain activities surrounding implementing new compounding laws and regulations
Detail the unique considerations involved in compounding for pediatric patients
4/14/2021: Drug Delivery Systems in Pediatrics
Lecture Speaker: Catherine Sherwin
Learning Objectives:
Understand the application of new methods of drug delivery to pediatrics
Consider the adaptation to pediatrics of new technologies (for example, nanotechnology)
Review methods of development of pediatric-specific devices
Discuss issues of IV drug delivery in pediatrics
4/21/2021: Considerations on the Impact of Adolescence on Drug Distribution and Effect
Lecture Speaker: Jeffrey Barrett
Learning Objectives: Pending Speaker Response
4/28/2021: Product Development for Rare Neurogenetic Disorders
Lecture Speaker: Mustafa Sahin
Learning Objectives:
Review basic principles of pediatric and rare disease product development, with emphasis in neurodevelopmental disorders.
Review recent advances in our understanding on rare neurodevelopmental disorders such as Tuberous Sclerosis, Rett Syndrome and Fragile X.
Discuss scientific, clinical and regulatory hurdles to overcome in order bring therapies to the clinic in these rare disorders.
5/5/2021: Parental Permission and Child Assent
Lecture Speaker: Donna Snyder
Learning Objectives:
Understand elements of informed consent
Understand reasonably foreseeable risks
Understand obtaining informed consent/assent from vulnerable subjects
Understand regulations governing informed consent
5/12/2021: Maximizing Opportunities in an Era of Team Science
Lecture Speaker: L. Michelle Bennett
Learning Objectives:
Understand some of the key characteristics that contribute to successful scientific team functioning
Understand the phases of team development
Understand the importance of trust during team development and maintenance
Learn about tools to help set expectations and hold team members accountable
Understand the importance of creating a shared vision for the team
Understand how values influence end results
5/19/2021: Bridging the Gap - Pediatric and Adult Clinical Pharmacology
Lecture Speaker: Anne Zajicek
Learning Objectives:
Understand developmental pharmacology changes from neonate, infant, child, and adolescent
Understand developmental pharmacology changes through the stages of adulthood
Understand what gaps exist between these two groups, and some bridging steps
5/26/2021: Clinical Applications of Pharmacometrics: Care at the Patient Level
Lecture Speaker: Sander Vinks
Learning Objectives:
Appreciate that the current drug development process results in doses for average patients but that individualized dosing strategies of drugs in neonates, infants and children are imperative to improve therapeutic response and/or lowering the risk of adverse events.
Have a better understanding of how state-of-the-art decision support using model-informed precision dosing may improve treatment outcomes by identifying the optimal dose for each individual patient.
Highlight examples of ongoing model-informed precision dosing studies and development in the pediatric community and at Cincinnati Children’s.
6/2/2021: Developmental Pharmacodynamics: The Next Great Information Gap in Pediatric Therapeutics
Lecture Speaker: Gregory Kearns
Learning Objectives:
Acquire a working understanding of where developmental PD is today and why it must be advanced if we are to improve pediatric therapeutics
Conceptually understand the framework of experimental approaches used to undertake pediatric PD research
Understand opportunities for support of research in pediatric PD
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Debbie Stein |
File Modified | 0000-00-00 |
File Created | 2021-04-23 |